All Stories

MaaT Pharma : Pioneering microbiome-driven therapy as new pillar in oncology

CEO Hervé Affagard discusses MaaT Pharma's new approach to microbiome-driven therapies and impressive Phase 3 results in treating acute Graft-versus Host disease.

Feb 10, 2025 - 16:31
 0
MaaT Pharma : Pioneering microbiome-driven therapy as new pillar in oncology
CEO Hervé Affagard discusses MaaT Pharma's new approach to microbiome-driven therapies and impressive Phase 3 results in treating acute Graft-versus Host disease.
Read More

Tags:

Previous Article

Walgreens: Bridging the gap between patient and medication

Next Article

Is it time for HLS to embrace industry-specific cloud?

Related Posts

Inside the Future of Aseptic Manufacturing with GRAM

Inside the Future of Aseptic Manufacturing with GRAM

Mar 7, 2025  0

Regulatory tracker: Bayer, BridgeBio's ATTR drug approved in EU

Regulatory tracker: Bayer, BridgeBio's ATTR drug approv...

Feb 12, 2025  0

Roche, Gilead top patient groups’ rankings of pharma ESG practices

Roche, Gilead top patient groups’ rankings of pharma ES...

Feb 28, 2025  0